<PAPER>
  <mode2 name="19158151_arathi" hasDoc="yes" version="1258"/>
  <TITLE>
    <s sid="1">Dietary grape seed proanthocyanidins inhibit 12-O-tetradecanoyl phorbol-13-acetate-caused skin tumor promotion in 7,12-dimethylbenz[a]anthracene-initiated mouse skin, which is associated with the inhibition of inflammatory responses <CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/></s>
  </TITLE>
  <ABSTRACT>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-1">
      <s sid="2">Grape seed proanthocyanidins (GSPs) possess anticarcinogenic activities.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac1" novelty="None" advantage="None"/></s>
      <s sid="3">Here, we assessed the effects of dietary GSPs on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin tumor promotion in 7,12-dimethylbenz[a]anthracene (DMBA)-initiated mouse skin.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="None" advantage="None"/></s>
      <s sid="4">Administration of dietary GSPs (0.2 and 0.5%, wt/wt) supplemented with control AIN76A diet resulted in significant inhibition of TPA-induced skin tumor promotion in C3H/HeN mice.<CoreSc1 atype="GSC" type="Res" conceptID="Res2" novelty="None" advantage="None"/></s>
      <s sid="5">The mice treated with GSPs developed a significantly lower tumor burden in terms of the percentage of mice with tumors (P&#8201;&lt;&#8201;0.05), total number of tumors per group (P&#8201;&lt;&#8201;0.01, n&#8201;=&#8201;20) and total tumor volume per tumor-bearing mouse (P&#8201;&lt;&#8201;0.01&#8211;0.001) as compared with the mice that received the control diet.<CoreSc1 atype="GSC" type="Res" conceptID="Res3" novelty="None" advantage="None"/></s>
      <s sid="6">GSPs also delayed the malignant progression of papillomas into carcinomas.<CoreSc1 atype="GSC" type="Res" conceptID="Res4" novelty="None" advantage="None"/></s>
      <s sid="7">As TPA-induced inflammatory responses are used routinely as markers of skin tumor promotion, we assessed the effect of GSPs on biomarkers of TPA-induced inflammation.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj2" novelty="None" advantage="None"/></s>
      <s sid="8">Immunohistochemical analysis and western blotting revealed that GSPs significantly inhibited expression of cyclooxygenase-2 (COX-2), prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) and markers of proliferation (proliferating cell nuclear antigen and cyclin D1) in both the DMBA-initiated/TPA-promoted mouse skin and skin tumors.<CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Res" conceptID="Res5" novelty="None" advantage="None"/></s>
      <s sid="9">In short-term experiments in which the mouse skin was treated with acute or multiple TPA applications, we found that dietary GSPs inhibited TPA-induced edema, hyperplasia, leukocytes infiltration, myeloperoxidase, COX-2 expression and PGE<sub>2</sub> production in the mouse skin.<CoreSc1 atype="GSC" type="Res" conceptID="Res6" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met2" novelty="None" advantage="None"/></s>
      <s sid="10">The inhibitory effect of GSPs was also observed against other structurally different skin tumor promoter-induced inflammation in the skin.<CoreSc1 atype="GSC" type="Res" conceptID="Res7" novelty="None" advantage="None"/></s>
      <s sid="11">Together, our results show that dietary GSPs inhibit chemical carcinogenesis in mouse skin and that the inhibition of skin tumorigenesis by GSPs is associated with the inhibition of inflammatory responses caused by tumor promoters.<CoreSc1 atype="GSC" type="Con" conceptID="Con1" novelty="None" advantage="None"/></s>
    </p>
  </ABSTRACT>
  <BODY>
    <SEC>
      <TITLE>Introduction</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-2">
        <s sid="12">The incidence of skin cancer is equivalent to the incidence of malignancies in all other organs combined (<xref class="xref-bibr" href="#ref-1" rid="xref-ref-1-1">1</xref>), and thus represents a major, and growing, public health problem.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac2" novelty="None" advantage="None"/></s>
        <s sid="13">The continuing increase in life expectancy, the depletion of the ozone layer that allows more solar ultraviolet (UV) radiation to reach at the surface of the Earth, together with changing dietary habits and lifestyle appear to be contributing factors for the increasing risk of skin cancer.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac3" novelty="None" advantage="None"/></s>
        <s sid="14">In addition to the morbidity and mortality associated with this disease, it is a major burden on the health care system as it has been estimated that the cost of treating non-melanoma and melanoma skin cancers in the USA is US$ 2.9 billion annually (<xref href="http://www.cancer.org/statistics">www.cancer.org/statistics</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac4" novelty="None" advantage="None"/></s>
        <s sid="15">Effective chemopreventive and chemotherapeutic agents and strategies to address this disease are being sought and one such strategy, the use of botanicals, is becoming increasingly popular in USA as a means to protect against skin disorders, including skin cancers.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac5" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-3">
        <s sid="16">Grapes (Vitis vinifera) are consumed worldwide.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac6" novelty="None" advantage="None"/></s>
        <s sid="17">They are rich in polyphenols, with 60&#8211;70% of grape polyphenols being found in the seeds, which are available as by-products of the industrial production of grape juice and wine.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac7" novelty="None" advantage="None"/></s>
        <s sid="18">The seeds contain a larger fraction of proanthocyanidins, which are primarily composed of dimers, trimers and oligomers of monomeric catechins or epicatechins (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-1">2</xref>&#8211;<xref class="xref-bibr" href="#ref-4" rid="xref-ref-4-1">4</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac8" novelty="None" advantage="None"/></s>
        <s sid="19">These grape seed proanthocyanidins (GSPs) have been shown to have antioxidant (<xref class="xref-bibr" href="#ref-5" rid="xref-ref-5-1">5</xref>,<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-1">6</xref>), anti-mutagenic, anti-inflammatory and anticarcinogenic (<xref class="xref-bibr" href="#ref-7" rid="xref-ref-7-1">7</xref>,<xref class="xref-bibr" href="#ref-8" rid="xref-ref-8-1">8</xref>) properties.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj3" novelty="None" advantage="None"/></s>
        <s sid="20">GSPs induce cytotoxic effects in various cancer cell lines (<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-1">9</xref>&#8211;<xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-1">11</xref>) with no apparent adverse biological effects on normal cells, i.e. human epidermal keratinocytes (<xref class="xref-bibr" href="#ref-5" rid="xref-ref-5-2">5</xref>,<xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-1">12</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac9" novelty="None" advantage="None"/></s>
        <s sid="21">We have shown previously that supplementation of the diet with GSPs inhibits UV radiation-induced skin carcinogenesis in SKH-1 hairless mice (<xref class="xref-bibr" href="#ref-8" rid="xref-ref-8-2">8</xref>), and long-term feeding of a GSPs-supplemented diet did not result in any apparent signs of toxicity in mice (<xref class="xref-bibr" href="#ref-8" rid="xref-ref-8-3">8</xref>,<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-2">9</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac10" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-4">
        <s sid="22">The development of skin cancer is a multistage process that includes initiation, promotion and progression in experimental animal models and possibly in human cancer includes induction and propagation (<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-1">13</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac11" novelty="None" advantage="None"/></s>
        <s sid="23">During the early tumor promotion stage of multistage carcinogenesis, the process is reversible but the initiation stage is irreversible and presumably unavoidable because of continuing exposure to carcinogenic chemicals and physical agents (<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-2">13</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac12" novelty="None" advantage="None"/></s>
        <s sid="24">A commonly used two-stage model of skin cancer involves initiation by treatment of the skin with 7,12-dimethylbenz(a)anthracene (DMBA) followed by promotion through treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac13" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-5">
        <s sid="25">In this study, we determined the effect of dietary GSPs on TPA-promoted skin tumor development in DMBA-initiated mouse skin and then examined the chemopreventive mechanism of GSPs in this model.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj4" novelty="None" advantage="None"/></s>
        <s sid="26">To our knowledge, this is the first study showing that dietary GSPs exert an antitumor promoting effect in TPA-promoted skin tumor development in DMBA-initiated mouse skin.<CoreSc1 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/></s>
        <s sid="27">We further show using this two-stage skin cancer model that the inhibition of TPA-caused skin tumor promotion by dietary GSPs is associated with the inhibition of TPA-induced inflammatory responses.<CoreSc1 atype="GSC" type="Con" conceptID="Con3" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Materials and methods</TITLE>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Animals, antibodies and reagents</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-6">
        <s sid="28">The female C3H/HeN mice (6&#8211;7 weeks old) used in these studies were purchased from Charles River Laboratory (Wilmington, MA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/></s>
        <s sid="29">All mice were maintained under standard conditions of a 12 h dark/12 h light cycle, a temperature of 24&#8201;&#177;&#8201;2&#176;C and relative humidity of 50&#8201;&#177;&#8201;10%.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/></s>
        <s sid="30">The mice were fed either a standard AIN76A control diet with or without GSPs (0.2 or 0.5%, wt/wt) and water ad libitum.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/></s>
        <s sid="31">The animal protocol used in this study was approved by the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp4" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-7">
        <s sid="32">Immunostaining-specific cyclooxygenase-2 (COX-2) antibody and a kit for prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) analysis were obtained from Cayman Chemicals (Ann Arbor, MI).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp5" novelty="None" advantage="None"/></s>
        <s sid="33">The antibodies used to detect proliferating cell nuclear antigen (PCNA) and cyclin D1 and secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp6" novelty="None" advantage="None"/></s>
        <s sid="34">TPA, mezerein, benzoylperoxide and anthralin were purchased from Sigma Chemical Co. (St Louis, MO) as were the trypsin, DNase and all other chemicals of analytical grade.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp7" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Dietary administration of GSPs</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-8">
        <s sid="35">We routinely receive GSPs from the Kikkoman Corporation (Tokyo, Japan) for our research.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp8" novelty="None" advantage="None"/></s>
        <s sid="36">Quality control of the GSPs is maintained by the company and it has been established that GSPs are stable for at least 2 years when refrigerated at 4&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp9" novelty="None" advantage="None"/></s>
        <s sid="37">The GSPs product contains &#8764;89% proanthocyanidins, with dimers (6.6%), trimers (5.0%), tetramers (2.9%) and oligomers (74.8%), as described earlier (<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-2">6</xref>,<xref class="xref-bibr" href="#ref-8" rid="xref-ref-8-4">8</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp10" novelty="None" advantage="None"/></s>
        <s sid="38">Experimental diets containing GSPs (0.2 and 0.5%, wt/wt) are prepared in pellet form in the AIN76A powdered control diet by TestDiet&#174; (Richmond, IN) for our research using the GSPs that we provide for this purpose.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp11" novelty="None" advantage="None"/></s>
        <s sid="39">In carcinogenesis studies, the GSP-supplemented diet was provided to the mice starting 1 week after initiation with DMBA or at the start of TPA application and continued until the termination of the experiment.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp12" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Skin tumorigenesis protocol: DMBA-initiated and TPA-promoted two-stage skin tumor protocol</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-9">
        <s sid="40">The dorsal skin area of the female C3H/HeN mice was shaved with electric clippers and depilated skin lotion was applied for 2&#8211;3 min.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp13" novelty="None" advantage="None"/></s>
        <s sid="41">The area was then washed with water.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp14" novelty="None" advantage="None"/></s>
        <s sid="42">Sixty mice received a single topical application of 400 nmol of DMBA in 0.2 ml of acetone (tumor initiation).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp15" novelty="None" advantage="None"/></s>
        <s sid="43">One week later, the mice were treated topically with TPA (10 nmol per mouse per 100 &#956;l acetone) (tumor promotion) and this treatment was repeated twice weekly throughout the course of the experiment.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp16" novelty="None" advantage="None"/></s>
        <s sid="44">The 60 mice that were treated with DMBA were randomly allocated into three treatment groups with 20 mice in each group.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp17" novelty="None" advantage="None"/></s>
        <s sid="45">All groups were treated with TPA.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp18" novelty="None" advantage="None"/></s>
        <s sid="46">Mice in group 1 were fed an unsupplemented standard AIN76A diet; mice in group 2 received the standard AIN76A diet supplemented with GSPs (0.2%, wt/wt) and mice in group 3 received the standard AIN76A diet supplemented with GSPs (0.5%, wt/wt).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp19" novelty="None" advantage="None"/></s>
        <s sid="47">The selection of the concentrations of GSPs in the diet was based on our prior studies in which dietary administration of GSPs as a supplement to an AIN76A diet inhibited UVB-induced oxidative stress (<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-3">6</xref>) as well as UVB-induced skin tumor development in mice (<xref class="xref-bibr" href="#ref-8" rid="xref-ref-8-5">8</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp20" novelty="None" advantage="None"/></s>
        <s sid="48">Two groups of control mice were used.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp21" novelty="None" advantage="None"/></s>
        <s sid="49">One group of mice (n&#8201;=&#8201;10) was treated with vehicle (0.2 ml acetone) alone twice a week and served as a negative control to assess spontaneous tumor induction.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp22" novelty="None" advantage="None"/></s>
        <s sid="50">A second group of mice (n&#8201;=&#8201;10) was initiated with the DMBA (400 nmol per mouse per 0.2 ml acetone) and 1 week later were provided a diet supplemented with GSPs (0.5%, wt/wt) until the termination of the experiment, as described for groups 1&#8211;3.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp23" novelty="None" advantage="None"/></s>
        <s sid="51">At the termination of the experiment, tumor samples and tumor-uninvolved skin samples were collected for the analysis of various biomarkers of interest as described below.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp24" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Short-term in vivo analysis of chemopreventive effects</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-10">
        <s sid="52">To determine the chemopreventive mechanism of GSPs on TPA-induced tumor promotion activities, we also conducted short-term in vivo experiments.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met3" novelty="None" advantage="None"/></s>
        <s sid="53">In these experiments, TPA (10 nmol per mouse per 200 &#956;l acetone) was applied topically to the shaved skin of C3H/HeN mice.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp25" novelty="None" advantage="None"/></s>
        <s sid="54">The TPA was either applied three times on alternate days (multiple treatments) and the mice were killed 6 h after the last treatment or the TPA was applied once and the mice were killed at 6, 12 or 24 h later (acute treatment).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp26" novelty="None" advantage="None"/></s>
        <s sid="55">The mice were either provided the unsupplemented standard AIN76A diet or the AIN76A diet supplemented with 0.5% (wt/wt) GSPs.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp27" novelty="None" advantage="None"/></s>
        <s sid="56">This concentration of GSPs was used as we had found that it significantly inhibited tumor promotion in the skin tumorigenesis protocol.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp28" novelty="None" advantage="None"/></s>
        <s sid="57">The GSP-supplemented diet was provided at least 1 week before the topical application of TPA.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp29" novelty="None" advantage="None"/></s>
        <s sid="58">Skin samples from the treated areas were collected at the time of killing for determining the effect of dietary GSPs on TPA-induced inflammatory responses.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp30" novelty="None" advantage="None"/></s>
        <s sid="59">In some experiments, structurally different tumor promoters (mezerein, benzoylperoxide, anthralin) were used in the place of TPA.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp31" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Evaluation of tumor growth</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-11">
        <s sid="60">The skin of the mice that had been subjected to the DMBA/TPA two-stage skin tumor protocol was examined once a week for the appearance of papillomas or tumors until the yield and size of the tumors had stabilized.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp32" novelty="None" advantage="None"/></s>
        <s sid="61">Growths that were &gt;1 mm in diameter and that persisted for at least 2 weeks were defined as tumors and recorded.<CoreSc1 atype="GSC" type="Met" conceptID="Met4" novelty="None" advantage="None"/></s>
        <s sid="62">The dimensions of all the tumors were recorded at the termination of the experiment and tumor volumes were calculated using the hemiellipsoid model formula: tumor volume = <span class="inline-formula" id="inline-formula-1"><img alt="Formula" class="math mml" src="520/embed/mml-math-1.gif"/></span>, where l = length, w = width and h = height.<CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Pathological evaluation of skin tumors</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-12">
        <s sid="63">At the termination of the skin tumor protocol, representative biopsies from all the skin tumors were collected, fixed in 10% formaldehyde and embedded in paraffin.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp33" novelty="None" advantage="None"/></s>
        <s sid="64">Deparafinized sections (5 &#956;m thick) were stained routinely with hematoxylin and eosin for pathological evaluation by three independent observers who were blinded to the source of the tissues.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp34" novelty="None" advantage="None"/></s>
        <s sid="65">The specimens were classified as tumors or non-neoplastic lesions according to the following criteria: loss of keratinization or keratinized centers, the presence of horn pearls and atypical cells.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp35" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Immunohistochemical detection of COX-2 and PCNA</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-13">
        <s sid="66">Five micrometer thick frozen sections were hydrated in phosphate-buffered saline (PBS) and then non-specific binding sites were blocked with 1% bovine serum albumin and 2% goat serum in PBS.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp36" novelty="None" advantage="None"/></s>
        <s sid="67">The sections were incubated with anti-COX-2 or anti-PCNA antibodies for 2 h at room temperature, washed and then incubated with biotinylated secondary antibody for 45 min followed by horseradish peroxidase-conjugated streptavidin.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp37" novelty="None" advantage="None"/></s>
        <s sid="68">After washing in PBS, sections were incubated with diaminobenzidine substrate and counterstained with hematoxylin.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp38" novelty="None" advantage="None"/></s>
        <s sid="69">Representative pictures were taken using a Nikon Eclipse E400 inverted microscope and DXM1200 digital camera.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp39" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Enzyme immunoassay for PGE<sub>2</sub></h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-14">
        <s sid="70">Skin or tumor samples were homogenized in 100 mM phosphate buffer, pH 7.4, containing 1 mM ethylenediaminetetraacetic acid and 10 &#956;M indomethacin using a polytron homogenizer (PT3100, Fisher Scientific, Atlanta, GA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp40" novelty="None" advantage="None"/></s>
        <s sid="71">The supernatants were collected and the concentration of PGE<sub>2</sub> was determined in supernatants using the Cayman PGE<sub>2</sub> Enzyme Immunoassay Kit (Ann Arbor, MI) following the manufacturer's protocol.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp41" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Preparation of tissue lysates and western blot analysis</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-15">
        <s sid="72">Epidermis or tumor samples were washed with cold PBS and lysed with ice-cold lysis buffer supplemented with protease inhibitors, as detailed previously (<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-4">6</xref>,<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-3">9</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp42" novelty="None" advantage="None"/></s>
        <s sid="73">Epidermis was separated from the whole skin as described earlier (<xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-1">14</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met6" novelty="None" advantage="None"/></s>
        <s sid="74">The epidermis or tumor tissue samples were pooled from at least three mice in each group, and three sets of pooled samples from each treatment group were used to prepare lysates, thus n&#8201;=&#8201;10.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp43" novelty="None" advantage="None"/></s>
        <s sid="75">For immunoblotting, proteins (20&#8211;35 &#956;g) were resolved on 10% Tris&#8211;glycine gels and transferred onto a nitrocellulose membrane.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp44" novelty="None" advantage="None"/></s>
        <s sid="76">After blocking the non-specific binding sites, the membrane was incubated with the primary antibody at 4&#176;C overnight.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp45" novelty="None" advantage="None"/></s>
        <s sid="77">The membrane was then incubated with the appropriate horseradish peroxidase-conjugated secondary antibody and the immunoreactive bands were visualized using the enhanced chemiluminescence reagent (Amersham Biosciences, Piscataway, NJ).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp46" novelty="None" advantage="None"/></s>
        <s sid="78">Membranes were then stripped and reprobed with anti-&#946;-actin antibody to verify equal protein loading.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp47" novelty="None" advantage="None"/></s>
        <s sid="79">The relative density (arbitrary) of each band after normalization for &#946;-actin is shown under each immunoblot as a fold-change compared with non-TPA-treated control, which has been assigned an arbitrary unit 1 in each case.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp48" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Leukocyte infiltration and myeloperoxidase assay</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-16">
        <s sid="80">Leukocyte infiltration and the levels of myeloperoxidase (MPO) were assessed in skin samples obtained from the mice subjected to the short-term in vivo analysis protocol.<CoreSc1 atype="GSC" type="Met" conceptID="Met7" novelty="None" advantage="None"/></s>
        <s sid="81">MPO was measured as a marker of tissue infiltration in skin homogenate samples following the procedure of Bradley et al. (<xref class="xref-bibr" href="#ref-15" rid="xref-ref-15-1">15</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met8" novelty="None" advantage="None"/></s>
        <s sid="82">Briefly, the skin samples were homogenized in 50 mM potassium phosphate buffer, pH 6.0, containing 0.5% hexadecyltrimethylammonium bromide followed by sonication of the homogenate at 4&#176;C for three 10 s bursts with a heat system sonicator equipped with a microprobe.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp49" novelty="None" advantage="None"/></s>
        <s sid="83">The resulting supernatants were used for MPO estimation.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp50" novelty="None" advantage="None"/></s>
        <s sid="84">MPO activity in the supernatant (0.1 ml) was assayed by mixing with 50 mM phosphate buffer (2.9 ml), pH 6.0, containing 0.167 mg/ml o-dianisidine dihydrochloride and 0.0005% hydrogen peroxide.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp51" novelty="None" advantage="None"/></s>
        <s sid="85">The change in absorbance resulting from decomposition of H<sub>2</sub>O<sub>2</sub> in the presence of o-dianisidine was measured at 460 nm using a Beckman Coulter DU 530 spectrophotometer.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp52" novelty="None" advantage="None"/></s>
        <s sid="86">The data are expressed as mean MPO U/mg protein.<CoreSc1 atype="GSC" type="Met" conceptID="Met9" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Skin edema</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-17">
        <s sid="87">Skin edema was assessed in the mice subjected to the short-term in vivo analysis protocol using the weight of 1 cm diameter skin punches and measurement of bi-fold skin thickness.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp53" novelty="None" advantage="None"/></s>
        <s sid="88">The 1 cm diameter skin punch biopsies were collected 6 h after treatment to the TPA or other inducers and immediately weighed on an electronic balance.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp54" novelty="None" advantage="None"/></s>
        <s sid="89">Bi-fold skin thickness was measured using spring-loaded micrometer.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp55" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Statistical analysis</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-18">
        <s sid="90">Statistical analysis of tumor data was performed at the termination of the experiment.<CoreSc1 atype="GSC" type="Met" conceptID="Met10" novelty="None" advantage="None"/></s>
        <s sid="91">Tumor incidence in the TPA alone and GSPs + TPA-treated groups was compared using the &#967;<sup>2</sup> test.<CoreSc1 atype="GSC" type="Met" conceptID="Met11" novelty="None" advantage="None"/></s>
        <s sid="92">Tumor multiplicity data were analyzed using the Wilcoxon rank-sum test.<CoreSc1 atype="GSC" type="Met" conceptID="Met12" novelty="None" advantage="None"/></s>
        <s sid="93">The results of PGE<sub>2</sub> and MPO are expressed as means &#177; SDs.<CoreSc1 atype="GSC" type="Met" conceptID="Met13" novelty="None" advantage="None"/></s>
        <s sid="94">The statistical significance of difference between the values of control and treatment groups was determined using the Student's t-test.<CoreSc1 atype="GSC" type="Met" conceptID="Met14" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Results</TITLE>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Dietary GSPs inhibit TPA-induced skin tumor promotion in DMBA-initiated mouse skin</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-19">
        <s sid="95">The GSP-supplemented diet reduced TPA-promoted skin tumor development in DMBA-initiated mouse skin in terms of tumor incidence (<xref class="xref-fig" href="#F1" rid="xref-fig-1-1">Figure 1A</xref>), tumor multiplicity (<xref class="xref-fig" href="#F1" rid="xref-fig-1-2">Figure 1B</xref>) and tumor size (<xref class="xref-fig" href="#F1" rid="xref-fig-1-3">Figure 1C</xref>) as compared with the control diet.<CoreSc1 atype="GSC" type="Res" conceptID="Res8" novelty="None" advantage="None"/></s>
        <s sid="96">The tumor incidence was 35% (P&#8201;&lt;&#8201;0.05) lower in the mice fed the diet supplemented with 0.5% GSPs than in the mice fed the unsupplemented control diet at the termination of the experiment (27th week).<CoreSc1 atype="GSC" type="Res" conceptID="Res9" novelty="None" advantage="None"/></s>
        <s sid="97">Although supplementation of the diet with the lower dose (0.2%) of GSPs resulted in a 20% lower tumor incidence, this effect did not reach statistical significance.<CoreSc1 atype="GSC" type="Res" conceptID="Res10" novelty="None" advantage="None"/></s>
        <s sid="98">Importantly, the tumors that developed in the mice fed the GSP-supplemented diets exhibited an increased latency period with a 4-week delay in the mice administered 0.2% GSPs and a 10-week delay in the mice administered 0.5% GSPs in the diet under the experimental conditions used in these studies.<CoreSc1 atype="GSC" type="Res" conceptID="Res11" novelty="None" advantage="None"/></s>
        <s sid="99">A total of 23 tumors were recorded in the group of mice that did not receive GSPs, whereas 13 tumors (43% inhibition, P&#8201;&lt;&#8201;0.01) were recorded in the group of mice fed 0.2% GSPs and only seven tumors (70% inhibition, P&#8201;&lt;&#8201;0.001) were recorded in the group of mice fed 0.5% GSPs (<xref class="xref-fig" href="#F1" rid="xref-fig-1-4">Figure 1B</xref> and <xref class="xref-table" href="#T1" rid="xref-table-wrap-1-1">Table I</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res12" novelty="None" advantage="None"/></s>
        <s sid="100">Additionally, the tumor size was significantly lower in the mice that were provided GSPs in the diet (32%, P&#8201;&lt;&#8201;0.01 in mice receiving 0.2% GSPs and 70%, P&#8201;&lt;&#8201;0.001 in mice receiving 0.5% GSPs) than in the mice receiving the control diet (<xref class="xref-fig" href="#F1" rid="xref-fig-1-5">Figure 1C</xref> and <xref class="xref-table" href="#T1" rid="xref-table-wrap-1-2">Table I</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res13" novelty="None" advantage="None"/></s>
        <s sid="101">Overall, both the rate of appearance of the TPA-induced tumors and their development in the GSP-treated mice was significantly lower (P&#8201;&lt;&#8201;0.05, Fisher&#8211;Irwin exact test) than in the mice that were not fed GSPs.<CoreSc1 atype="GSC" type="Res" conceptID="Res14" novelty="None" advantage="None"/></s>
        <s sid="102">The mice in the control group that were treated with vehicle alone or treated with GSPs did not develop tumors within the 27-week study period.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs1" novelty="None" advantage="None"/></s>
        <s sid="103">During the carcinogenesis protocol, the body weights and food and water intakes did not differ among the experimental groups (data not shown), suggesting that administration of dietary GSPs does not produce any apparent signs of toxicity in mice at least at the concentrations used and within the time frame of the current experiments.<CoreSc1 atype="GSC" type="Res" conceptID="Res15" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-26">
        <s sid="104">Histopathologic examination of the tumors at the termination of the experiment revealed that of the 23 tumors in the group of mice that received the unsupplemented control diet, four were squamous cell carcinomas, 15 squamous cell papillomas and four keratoacanthomas.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs2" novelty="None" advantage="None"/></s>
        <s sid="105">Of the 13 tumors in the group of mice that received the diet supplemented with 0.2% GSPs, one was squamous cell carcinoma, 10 were squamous cell papillomas and two keratoacanthomas; whereas, of the seven tumors in the group of mice that were provided 0.5% GSPs, there were six squamous cell papillomas and one keratoacanthoma.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs3" novelty="None" advantage="None"/></s>
        <s sid="106">Thus, the majority of tumors were squamous cell papillomas and were of epidermal origin.<CoreSc1 atype="GSC" type="Res" conceptID="Res16" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Dietary GSPs delayed the malignant progression of papillomas to carcinomas</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-27">
        <s sid="107">Although 20% of the mice that were provided the control diet developed carcinoma, only 5% of the mice that were provided 0.2% GSPs developed carcinoma, and none of the mice which were provided 0.5% GSPs developed carcinoma during the entire treatment protocol.<CoreSc1 atype="GSC" type="Res" conceptID="Res17" novelty="None" advantage="None"/></s>
        <s sid="108">The total number of carcinomas at the termination of the experiment in the group of mice that received the control diet was four; therefore, 17% of the papillomas were converted into carcinomas in this group; whereas, only one carcinoma was recorded in the group of mice that were provided 0.2% GSPs and only 7.7% of the papillomas were converted into carcinomas in this group.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs4" novelty="None" advantage="None"/></s>
        <s sid="109">Taken together with the absence of carcinomas in the group of mice that were provided 0.5% GSPs, these data suggest that the risk of malignant progression of papillomas into carcinomas in GSP-treated mice was significantly reduced compared with the control mice that were not given GSPs in the diet.<CoreSc1 atype="GSC" type="Res" conceptID="Res18" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Effect of dietary GSPs on TPA-induced inflammation and its mediators</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-28">
        <s sid="110">Chronic inflammation has been shown to promote tumor development (<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-3">13</xref>,<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-1">16</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac14" novelty="None" advantage="None"/></s>
        <s sid="111">As supplementation of the AIN76A control diet with 0.5% GSPs significantly inhibited TPA-induced skin tumor promotion in mice in the chemical carcinogenesis protocol (<xref class="xref-fig" href="#F1" rid="xref-fig-1-6">Figure 1</xref>), we used the skin and tumor samples from this group and control group for further mechanistic analysis.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot1" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Dietary GSPs inhibit the levels of COX-2 expression and PGE<sub>2</sub> production in mouse skin and skin tumors </h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-29">
        <s sid="112">A characteristic response of keratinocytes to tumor promoters is enhanced COX-2 expression and a subsequent increase in the production of PG metabolites in the skin (<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-4">13</xref>,<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-2">16</xref>); moreover, elevated expression of COX-2 and prostaglandin (PG) metabolites has been observed in squamous and basal cell carcinomas of the skin (<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-3">16</xref>,<xref class="xref-bibr" href="#ref-17" rid="xref-ref-17-1">17</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac15" novelty="None" advantage="None"/></s>
        <s sid="113">Of the PG metabolites, PGE<sub>2</sub> appears to play a pivotal role in tumor promotion.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac16" novelty="None" advantage="None"/></s>
        <s sid="114">Immunohistochemical analysis confirmed that, in mice that were fed the unsupplemented control diet, the expression of COX-2 was higher in the skin of DMBA/TPA-treated mice than in skin of the mice that were not treated with DMBA/TPA (<xref class="xref-fig" href="#F2" rid="xref-fig-2-1">Figure 2A</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res19" novelty="None" advantage="None"/></s>
        <s sid="115">The expression of COX-2 in the skin of the DMBA/TPA-treated mice that were provided the GSP-supplemented diet was lower than that in the skin of the DMBA/TPA-treated mice that were fed the unsupplemented control diet (<xref class="xref-fig" href="#F2" rid="xref-fig-2-2">Figure 2A</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res20" novelty="None" advantage="None"/></s>
        <s sid="116">Similarly, the levels of COX-2 expression in the skin tumors were lower in the DMBA/TPA-treated mice that were provided the GSP-supplemented diet than in the tumors in the mice that were provided the control diet (<xref class="xref-fig" href="#F2" rid="xref-fig-2-3">Figure 2B</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res21" novelty="None" advantage="None"/></s>
        <s sid="117">These data were confirmed by western blot analysis, which showed higher expression levels of COX-2 protein in DMBA/TPA-treated mouse skin and skin tumors and GSPs inhibition of this DMBA/TPA-induced elevation in the expression levels of COX-2 in the mouse skin and skin tumors (<xref class="xref-fig" href="#F2" rid="xref-fig-2-4">Figure 2C</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs5" novelty="None" advantage="None"/></s>
        <s sid="118">As shown in <xref class="xref-fig" href="#F2" rid="xref-fig-2-5">Figure 2D</xref>, we also found that the levels of PGE<sub>2</sub> in the skin and tumors of the DMBA/TPA-treated mice were significantly higher (P&#8201;&lt;&#8201;0.001) than non-DMBA/TPA-treated mouse skin samples.<CoreSc1 atype="GSC" type="Res" conceptID="Res22" novelty="None" advantage="None"/></s>
        <s sid="119">The administration of GSPs significantly inhibited (P&#8201;&lt;&#8201;0.01) the DMBA/TPA-induced elevation in the levels of PGE<sub>2</sub> in both skin and skin tumors.<CoreSc1 atype="GSC" type="Res" conceptID="Res23" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Dietary GSPs inhibit DMBA/TPA-induced increases in the levels of PCNA and cyclin D1 in the skin and skin tumors</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-31">
        <s sid="120">The proliferation potential of epidermal cells (i.e. the hyperplastic response) is another marker of the TPA-induced inflammatory reaction in the skin.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac17" novelty="None" advantage="None"/></s>
        <s sid="121">Immunohistochemical analysis revealed that DMBA/TPA application enhances the proliferation potential of epidermal keratinocytes as indicated by the PCNA staining pattern in the epidermis and that GSPs inhibited this DMBA/TPA-induced expression of PCNA in both skin (<xref class="xref-fig" href="#F3" rid="xref-fig-3-1">Figure 3A</xref>) and skin tumor (<xref class="xref-fig" href="#F3" rid="xref-fig-3-2">Figure 3B</xref>) samples.<CoreSc1 atype="GSC" type="Res" conceptID="Res24" novelty="None" advantage="None"/></s>
        <s sid="122">These data were further confirmed by western blot analysis, as shown in <xref class="xref-fig" href="#F3" rid="xref-fig-3-3">Figure 3C</xref>.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs6" novelty="None" advantage="None"/></s>
        <s sid="123">Similarly, western blot analysis revealed that dietary GSPs inhibited DMBA/TPA-induced increase in the expression levels of cyclin D1 in both skin and skin tumor samples (<xref class="xref-fig" href="#F3" rid="xref-fig-3-4">Figure 3C</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs7" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Short-term in vivo studies</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-33">
        <s sid="124">To further verify whether antitumor promotion effect of GSPs is associated with the inhibition of TPA-induced inflammatory responses, short-term experiments were performed.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa2" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Dietary GSPs inhibit TPA-induced epidermal hyperplastic response</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-34">
        <s sid="125">It was evident from the hematoxylin and eosin staining (<xref class="xref-fig" href="#F4" rid="xref-fig-4-1">Figure 4A</xref>) of the skin samples that the thickness of the epidermis is greater in the TPA-treated than in the non-TPA-treated mouse skin, which suggests a hyperplastic response to this tumor promoter; furthermore, the dietary GSPs inhibited this TPA-induced hyperplastic response in the skin.<CoreSc1 atype="GSC" type="Res" conceptID="Res25" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Con" conceptID="Con4" novelty="None" advantage="None"/></s>
        <s sid="126">We therefore measured the epidermal thickness at five equidistant points along the entire length of the section from the dermo-epidermal junction to the top of stratum corneum, and all five values were averaged and reported as the mean epidermal thickness in micrometers.<CoreSc1 atype="GSC" type="Met" conceptID="Met15" novelty="None" advantage="None"/></s>
        <s sid="127">Similarly, the numbers of cell layers were counted from the dermo-epidermal junction to the bottom of the stratum corneum to determine the mean vertical thickness of cell layers in the epidermis.<CoreSc1 atype="GSC" type="Met" conceptID="Met16" novelty="None" advantage="None"/></s>
        <s sid="128">As shown in <xref class="xref-fig" href="#F4" rid="xref-fig-4-2">Figure 4A</xref>, 6 h after multiple TPA treatments, there was a significant increase in mean epidermal thickness (70&#8201;&#177;&#8201;10 &#956;m) and mean vertical thickness of epidermal cell layers (6&#8201;&#177;&#8201;2) compared with the acetone-treated normal mouse skin (20.5&#8201;&#177;&#8201;5.0 &#956;m thick and 2&#8201;&#177;&#8201;1 cell layers).<CoreSc1 atype="GSC" type="Res" conceptID="Res26" novelty="None" advantage="None"/></s>
        <s sid="129">In mice provided the GSP-supplemented diet, there was a significant reduction (&gt;50%, P&#8201;&lt;&#8201;0.01) in this TPA-induced increase in epidermal thickness (39&#8201;&#177;&#8201;5 &#956;m) and vertical thickness of epidermal cell layers (4&#8201;&#177;&#8201;1).<CoreSc1 atype="GSC" type="Res" conceptID="Res27" novelty="None" advantage="None"/></s>
        <s sid="130">Similar effects of GSPs were also observed when mice were treated once with TPA and the effects were determined 12 and 24 h later (<xref class="xref-fig" href="#F4" rid="xref-fig-4-3">Figure 4A</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs8" novelty="None" advantage="None"/></s>
        <s sid="131">Dietary GSPs alone, however, did not induce an epidermal hyperplastic response in mouse skin (<xref class="xref-fig" href="#F4" rid="xref-fig-4-4">Figure 4A</xref>, upper panels).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs9" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Dietary GSPs inhibit structurally different skin tumor promoter-induced inflammatory responses</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-36">
        <s sid="132">Development of edema is considered as a marker of inflammation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac18" novelty="None" advantage="None"/></s>
        <s sid="133">As determined by the weight of a 1 cm diameter punch of the skin, treatment of the skin with TPA resulted in a significantly higher skin punch weight (50% more, P&#8201;&lt;&#8201;0.01).<CoreSc1 atype="GSC" type="Res" conceptID="Res28" novelty="None" advantage="None"/></s>
        <s sid="134">The provision of the GSP-supplemented diet significantly reduced (46%, P&#8201;&lt;&#8201;0.01) the TPA-induced increase in punch weight, as shown in <xref class="xref-table" href="#T2" rid="xref-table-wrap-2-1">Table II</xref>.<CoreSc1 atype="GSC" type="Res" conceptID="Res29" novelty="None" advantage="None"/></s>
        <s sid="135">Similarly, provision of the GSP-supplemented diet reduced the increases in punch weight induced by multiple TPA applications.<CoreSc1 atype="GSC" type="Res" conceptID="Res30" novelty="None" advantage="None"/></s>
        <s sid="136">On analysis of the effects of dietary GSPs on the increase in punch weight induced by topical application of other structurally different skin tumor promoters, mezerein, benzoylperoxide and anthralin, we found that the GSPs also inhibited the induction of edema in terms of skin punch weight caused by these tumor promoters (<xref class="xref-table" href="#T2" rid="xref-table-wrap-2-2">Table II</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res31" novelty="None" advantage="None"/></s>
        <s sid="137">To further verify the inhibitory effect of GSPs on tumor promoter-induced edema, we measured the bi-fold skin thickness before tumor promoter application and 6 h after acute treatment of various tumor promoters.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa3" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met17" novelty="None" advantage="None"/></s>
        <s sid="138">As shown in <xref class="xref-table" href="#T2" rid="xref-table-wrap-2-3">Table II</xref>, the bi-fold skin thickness was increased significantly after acute (43%, P&#8201;&lt;&#8201;0.01) or multiple TPA treatment (73%, P&#8201;&lt;&#8201;0.005).<CoreSc1 atype="GSC" type="Res" conceptID="Res32" novelty="None" advantage="None"/></s>
        <s sid="139">Provision of the GSP-supplemented diet significantly inhibited TPA-induced edema in terms of bi-fold thickness of the skin after acute (50%, P&#8201;&lt;&#8201;0.01) and multiple treatment (41%, P&#8201;&lt;&#8201;0.01) with TPA.<CoreSc1 atype="GSC" type="Res" conceptID="Res33" novelty="None" advantage="None"/></s>
        <s sid="140">Dietary GSPs also significantly inhibited the development of edema in terms of bi-fold skin thickness caused by other structurally different skin tumor promoters, as shown in <xref class="xref-table" href="#T2" rid="xref-table-wrap-2-4">Table II</xref>.<CoreSc1 atype="GSC" type="Res" conceptID="Res34" novelty="None" advantage="None"/></s>
        <s sid="141">Dietary GSPs alone did not affect the thickness of the skin, suggesting that GSPs alone do not induce inflammation in the mouse skin.<CoreSc1 atype="GSC" type="Res" conceptID="Res35" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-42">
        <s sid="142">Infiltrating leukocytes are considered to be a major source of inflammatory reactions and oxidative stress (<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-5">13</xref>,<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-4">16</xref>,<xref class="xref-bibr" href="#ref-18" rid="xref-ref-18-1">18</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac19" novelty="None" advantage="None"/></s>
        <s sid="143">Routine hematoxylin and eosin staining of skin samples revealed that the skin treatment with TPA induces infiltration of inflammatory leukocytes (activated monocytes/macrophages and neutrophils) that peaks around 12&#8211;24 h post-TPA application (<xref class="xref-fig" href="#F4" rid="xref-fig-4-5">Figure 4A</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res36" novelty="None" advantage="None"/></s>
        <s sid="144">It was observed that provision of the GSP-supplemented diet markedly reduced the number of TPA-induced infiltrating leukocytes in the treated skin sites at 12 and 24 h post-TPA treatment.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs10" novelty="None" advantage="None"/></s>
        <s sid="145">This inhibitory effect of GSPs on TPA-induced leukocyte infiltration was also evident after multiple treatment of skin with TPA.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs11" novelty="None" advantage="None"/></s>
        <s sid="146">To confirm that dietary GSPs inhibit TPA-induced infiltration of leukocytes in the treated sites, we determined the levels of MPO in skin homogenate samples from the various treatment groups.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa4" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met18" novelty="None" advantage="None"/></s>
        <s sid="147">We found an increase in MPO activity in skin samples after treatment with TPA (<xref class="xref-fig" href="#F4" rid="xref-fig-4-6">Figure 4B</xref>), suggesting an influx of leukocytes into the inflamed skin.<CoreSc1 atype="GSC" type="Res" conceptID="Res37" novelty="None" advantage="None"/></s>
        <s sid="148">The provision of the GSP-supplemented diet significantly inhibited (P&#8201;&lt;&#8201;0.01) TPA-induced MPO activity both after acute and multiple treatments of the skin with TPA and at all the time points studied.<CoreSc1 atype="GSC" type="Res" conceptID="Res38" novelty="None" advantage="None"/></s>
        <s sid="149">This GSP-induced reduction in MPO activity further suggests that the GSPs act, at least in part, to inhibit the TPA-induced inflammatory responses in the skin.<CoreSc1 atype="GSC" type="Con" conceptID="Con5" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Dietary GSPs inhibit TPA-induced COX-2 expression and PGE<sub>2</sub> production in mouse skin </h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-43">
        <s sid="150">As tumor promoter-induced COX-2 expression and a subsequent increase in the production of PG metabolites in the skin are considered as characteristic responses to inflammation, we further determined whether dietary GSPs inhibit TPA-induced COX-2 expression and thereby inhibit PGE<sub>2</sub> production in mouse skin.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp1" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Bac" conceptID="Bac20" novelty="None" advantage="None"/></s>
        <s sid="151">Western blot analysis revealed that treatment of the mouse skin with TPA, either as a single or multiple applications, resulted in higher levels of COX-2 expression as compared with non-TPA-treated normal mouse skin (<xref class="xref-fig" href="#F4" rid="xref-fig-4-7">Figure 4C</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res39" novelty="None" advantage="None"/></s>
        <s sid="152">Provision of the GSP (0.5%, wt/wt)-supplemented diet resulted in inhibition of this TPA-induced increase in COX-2 expression at all time points studied after a single or multiple applications of TPA.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs12" novelty="None" advantage="None"/></s>
        <s sid="153">Similarly, dietary GSPs significantly inhibited (P&#8201;&lt;&#8201;0.01) TPA-induced increases in the levels of PGE<sub>2</sub> after both single and multiple TPA treatments (<xref class="xref-fig" href="#F4" rid="xref-fig-4-8">Figure 4D</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res40" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Discussion</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-44">
        <s sid="154">In our continuing efforts to develop newer and more effective dietary botanicals for the prevention of skin cancer, we first assessed the efficacy of dietary GSPs using a two-stage skin chemical carcinogenesis protocol.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa5" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met19" novelty="None" advantage="None"/></s>
        <s sid="155">In this study, we used the inbred C3H/HeN strain of mice as these mice can be appropriately used to study the effects of the tumor promoters, and the modification of these effects by GSPs, on inflammatory responses.<CoreSc1 atype="GSC" type="Met" conceptID="Met20" novelty="None" advantage="None"/></s>
        <s sid="156">The central finding of the present study is that dietary GSPs afford significant protection against TPA-induced skin tumor development in DMBA-initiated mouse skin, and the antitumor promotion effects are associated with the anti-inflammatory effects of the GSPs.<CoreSc1 atype="GSC" type="Con" conceptID="Con6" novelty="None" advantage="None"/></s>
        <s sid="157">Further, as the development of papillomas was delayed and growth slowed with GSPs treatment, GSPs also delayed the malignant conversion of papillomas to carcinomas.<CoreSc1 atype="GSC" type="Con" conceptID="Con7" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-45">
        <s sid="158">A wide range of studies have shown that naturally occurring polyphenols, specifically those present in fruits and vegetables, common beverages, like green tea, and several herbs and plants with diverse pharmacological activities, are a promising classes of agents with the potential to act to inhibit tumor promotion (<xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-1">19</xref>&#8211;<xref class="xref-bibr" href="#ref-23" rid="xref-ref-23-1">23</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac21" novelty="None" advantage="None"/></s>
        <s sid="159">Green tea is a widely consumed beverage worldwide and the composition of GSPs differs from green tea polyphenols in their unique combination of proanthocyanidins, which are polyphenols but with a higher molecular weight than the green tea polyphenols.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac22" novelty="None" advantage="None"/></s>
        <s sid="160">GSPs are a mixture of dimers, trimers, tetramers and oligomers of monomeric catechin and epicatechin (<xref class="xref-bibr" href="#ref-7" rid="xref-ref-7-2">7</xref>); whereas green tea polyphenols are mainly composed of monomers, such as catechins, epicatechins and their gallate esters, including (&#8722;)-epigallocatechin-3-gallate (<xref class="xref-bibr" href="#ref-24" rid="xref-ref-24-1">24</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac23" novelty="None" advantage="None"/></s>
        <s sid="161">However, the activity of dietary GSPs in inhibiting tumor promotion in the skin chemical carcinogenesis model used in these studies appears identical to the activity of green tea polyphenols in inhibiting tumor promotion in the skin (<xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-1">20</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac24" novelty="None" advantage="None"/></s>
        <s sid="162">With the notion that targeting the tumor promotion stage could be a better strategy for the prevention of cancer, regular consumption of vegetables and fruits that are good source of polyphenols has been associated with a reduced risk for several malignancies (<xref class="xref-bibr" href="#ref-25" rid="xref-ref-25-1">25</xref>&#8211;<xref class="xref-bibr" href="#ref-29" rid="xref-ref-29-1">29</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac25" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-46">
        <s sid="163">It has been recognized that inhibition of tumor promotion is most probably a better strategy for cancer chemoprevention than inhibition of the tumor initiation stage because initiation is a short irreversible event, whereas the tumor promotion stage is reversible during the early stages (<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-6">13</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac26" novelty="None" advantage="None"/></s>
        <s sid="164">It is well established that tumor promoters, such as TPA, induce inflammation and the mediators of inflammation are considered to be potent regulators of tumor promotion in skin cancers (<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-7">13</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac27" novelty="None" advantage="None"/></s>
        <s sid="165">We have shown earlier that topical application of TPA on the mouse skin enhances the expression of COX-2 (<xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-2">20</xref>), which is one of the most important enzymes responsible for the development of inflammation and tumors.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac28" novelty="None" advantage="None"/></s>
        <s sid="166">COX-2 is a rate-limiting enzyme for generation of PG metabolites from arachidonic acid (<xref class="xref-bibr" href="#ref-30" rid="xref-ref-30-1">30</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac29" novelty="None" advantage="None"/></s>
        <s sid="167">COX-2 overexpression has been linked to the pathophysiology of inflammation and cancer due to enhanced synthesis of PG metabolites (<xref class="xref-bibr" href="#ref-31" rid="xref-ref-31-1">31</xref>), which have been shown to be potential contributing factor in chemical carcinogenesis.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac30" novelty="None" advantage="None"/></s>
        <s sid="168">In this study, we found that dietary GSPs inhibit the elevation in the expression of COX-2 and greater production of PGE<sub>2</sub> induced by chronic TPA exposure of DMBA-initiated mouse skin in both the skin and skin tumors, which may have contributed to the inhibition of the skin tumor development in the GSP-treated mice.<CoreSc1 atype="GSC" type="Con" conceptID="Con8" novelty="None" advantage="None"/></s>
        <s sid="169">The decreased proliferating potential of epidermal keratinocytes by dietary GSPs, which is indicated by the reduced expression of the PCNA and cyclin D1 proteins in the DMBA/TPA-induced skin and skin tumors, may also be contributing factors for the inhibitory effects of GSPs on the development of skin tumors.<CoreSc1 atype="GSC" type="Con" conceptID="Con9" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-47">
        <s sid="170">The infiltration and accumulation of activated macrophages and neutrophils after TPA treatment of the mouse skin is a characteristic feature of skin inflammation, and the quantification of infiltrating leukocytes in skin is used routinely as a measure for the intensity of inflammation (<xref class="xref-bibr" href="#ref-15" rid="xref-ref-15-2">15</xref>,<xref class="xref-bibr" href="#ref-32" rid="xref-ref-32-1">32</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac31" novelty="None" advantage="None"/></s>
        <s sid="171">The levels of MPO also are commonly used as a quantitative marker of inflammatory infiltrates since normal skin exhibits low background levels of MPO, whereas skin that is inflamed by an infection, wounding or by the application of phorbol ester and other tumor promoters enhances the levels of MPO (<xref class="xref-bibr" href="#ref-15" rid="xref-ref-15-3">15</xref>,<xref class="xref-bibr" href="#ref-32" rid="xref-ref-32-2">32</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac32" novelty="None" advantage="None"/></s>
        <s sid="172">Our analysis of the effects of GSPs on the immediate responses induced by a single application of TPA in short-term in vivo experiments showed that dietary GSPs inhibited the infiltration of leukocytes in the mouse skin as well as reducing the levels of MPO activity at all the time points studied.<CoreSc1 atype="GSC" type="Res" conceptID="Res41" novelty="None" advantage="None"/></s>
        <s sid="173">Additionally, dietary GSPs reduced TPA-induced skin punch weight and bi-fold skin thickness, which were analyzed as markers of edema.<CoreSc1 atype="GSC" type="Res" conceptID="Res42" novelty="None" advantage="None"/></s>
        <s sid="174">TPA-induced edema is considered to be a marker of tissue inflammation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac33" novelty="None" advantage="None"/></s>
        <s sid="175">Notably, we confirmed that GSPs have the ability to inhibit various structurally different skin tumor promoter-induced inflammatory responses in the mouse skin.<CoreSc1 atype="GSC" type="Res" conceptID="Res43" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-48">
        <s sid="176">Collectively, the data from the present study suggest that dietary GSPs have anti-skin tumor promotion activity and that the antitumor promotion activity of GSPs is associated with the inhibition of tumor promoter-induced inflammation in mouse skin.<CoreSc1 atype="GSC" type="Con" conceptID="Con10" novelty="None" advantage="None"/></s>
        <s sid="177">The results of the present study, in conjunction with prior publications from our laboratory and others, suggest that GSPs may prove to be useful chemopreventive agent against some forms of human cancers induced by environmental agents, and therefore, more detailed studies with particular emphasis on molecular mechanisms could lead to new strategies for cancer chemoprevention in humans.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot2" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Funding</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-49">
        <s sid="178">Veterans Administration Merit Review Award to S.K.K.</s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Acknowledgments</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-60">
        <s sid="179">Conflict of Interest Statement: None declared.</s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Footnotes</TITLE>
    </SEC>
    <SEC>
      <TITLE>References</TITLE>
    </SEC>
  </BODY>
</PAPER>